This company has been acquired
STSA Stock Overview
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Satsuma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$8.08 |
| 52 Week Low | US$0.59 |
| Beta | 0.10 |
| 1 Month Change | 3.77% |
| 3 Month Change | 19.59% |
| 1 Year Change | -67.46% |
| 3 Year Change | -95.92% |
| 5 Year Change | n/a |
| Change since IPO | -93.49% |
Recent News & Updates
Recent updates
Can Satsuma Pharmaceuticals (NASDAQ:STSA) Afford To Invest In Growth?
Feb 15
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Sep 02Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
May 13Satsuma Pharmaceuticals: Sizing Up This One Trick Pony
Nov 07Satsuma shares surge on data from early-stage STS101 trial
Jun 16Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?
Jan 26Shareholder Returns
| STSA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.8% | -3.2% | -3.5% |
| 1Y | -67.5% | 11.7% | 20.2% |
Return vs Industry: STSA underperformed the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: STSA underperformed the US Market which returned 5% over the past year.
Price Volatility
| STSA volatility | |
|---|---|
| STSA Average Weekly Movement | 20.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: STSA's share price has been volatile over the past 3 months.
Volatility Over Time: STSA's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 25 | John Kollins | www.satsumarx.com |
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company’s product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals, Inc. Fundamentals Summary
| STSA fundamental statistics | |
|---|---|
| Market cap | US$36.47m |
| Earnings (TTM) | -US$64.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs STSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.83m |
| Earnings | -US$64.83m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did STSA perform over the long term?
See historical performance and comparison